Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 9 | 1 | 0,00 % | ||
| ULTRAGENYX | 8 | - | -3,08 % | ||
| REGENERON PHARMACEUTICALS | 6 | 22 | -1,15 % | ||
| BIONTECH | 6 | 13 | +0,13 % | ||
| BIOGEN | 3 | 54 | -0,20 % | ||
| HARMONY BIOSCIENCES | 3 | 17 | 0,00 % | ||
| APELLIS PHARMACEUTICALS | 3 | 4 | -0,19 % | ||
| ORIC PHARMACEUTICALS | 3 | 2 | -0,65 % | ||
| ESPERION | 3 | - | +0,75 % | ||
| CENTESSA PHARMACEUTICALS | 3 | - | -1,74 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:06 | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12:46 | AnaptysBio gliedert First Tracks Biotherapeutics aus: Handel an der NASDAQ startet am 20. April | 1 | Investing.com Deutsch | ||
| 11:30 | Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; Eli Lilly Acquires CNTA; BIIB Snaps Up APLS | 360 | AFX News | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| 00:26 | Grifols' Canadian licence restricted after plasma donor deaths | 2 | Financial Post | ||
| Do | NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Do | Oppenheimer reiterates Pharvaris stock rating on trial timeline | 1 | Investing.com | ||
| Do | Truist senkt Kursziel für Upstream Bio wegen verzögertem Studienzeitplan | 4 | Investing.com Deutsch | ||
| Do | Vanda Pharmaceuticals: Chefjurist Timothy Williams kündigt Rücktritt an | 4 | Investing.com Deutsch | ||
| Do | Truist cuts Upstream Bio stock price target on trial timeline | 2 | Investing.com | ||
| Do | Regeneron partners with TriNetX for health data access | 5 | Investing.com | ||
| Do | TriNetX, LLC.: TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions | 312 | PR Newswire | Under the collaboration, TriNetX will provide Regeneron with secure, licensed access to TriNetX's current and future de-identified health data from approximately 300 million individuals (170 million... ► Artikel lesen | |
| Do | Regeneron Pharmaceuticals, Inc.: Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions | 3 | GlobeNewswire (USA) | ||
| Do | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Do | Esperion sells Japan royalty rights for $50 million to Athyrium | 13 | Investing.com | ||
| Do | Relay Therapeutics, Inc.: Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 | 8 | GlobeNewswire (USA) | ||
| Do | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | 4 | GlobeNewswire (USA) | ||
| Do | Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| Do | Esperion Therapeutics, Inc.: Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) | 55 | GlobeNewswire (Europe) | - Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued... ► Artikel lesen | |
| Do | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 231 | Business Wire | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| Do | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.